George Clinical presents its kidney research expertise during the ERA-EDTA Virtual Congress this month. Sessions include David Wheeler, Hiddo Lambers Heerspink and Jonathan Barratt. View the program and presentations here.
For more information on our scientific leaders, their abstracts and how we can support your study, please contact Matthew Reabold at [email protected]
Professor Heerspink’s principal research interests include optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease in patients with diabetes with a specific focus on personalized medicine. He is Professor of Clinical Trials and Personalized Medicine; Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands; and visiting professor at the University of New South Wales in Sydney. He worked as a Postdoctoral Fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with chronic kidney disease.
Professor Heerspink leads and participates in clinical trials focused on renal and cardiovascular complications of Type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. Based on his work at The George Institute, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organization of scientific research and received in 2016 the Galien award for his research.
Professor Barratt’s research is focused on pathogenesis of IgA nephropathy and a range of areas across renal medicine including glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anaemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and leads the Renal Research Group within the College of Life Sciences, University of Leicester. He also participates in other IgA nephrology initiatives such as the International IgA Nephropathy Network and in workgroups identifying endpoints for clinical trials such as the FDA and ASN Kidney Health Initiative.
Professor Barratt has been Principal Investigator for international randomized controlled clinical trials in IgA nephropathy and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants committee.
Dr. Wheeler’s research interests are in chronic kidney disease complications, specifically those that increase cardiovascular disease burden and/or accelerate kidney failure progression. He is Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Professor of Kidney Medicine at University College London. He has participated in developing and running several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, and sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease. He has developed clinical practice guidelines for several organizations.
Dr. Wheeler is a Research Partner with The George Institute for Global Health and has developed clinical practice guidelines for several organizations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Clinical Lead for Division 2 of the North Thames Clinical Research Network and heads a team of eight Clinical Trials Nurses/Practitioners at the Centre for Nephrology, Royal Free Hospital in London. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.
Meet with George Clinical! Contact us to schedule a time now.